Giovanni Abbadessa Selected Research

ARQ 197

1/2018	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
2/2017	Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma.
11/2016	Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.
3/2015	Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers.
4/2014	Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial.
1/2013	Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
1/2013	Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model.
1/2012	Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown.
12/2011	A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Giovanni Abbadessa Research Topics

Disease

24	Neoplasms (Cancer) 01/2022 - 01/2007
11	Hepatocellular Carcinoma (Hepatoma) 02/2018 - 10/2010
4	Fibrosis (Cirrhosis) 02/2018 - 01/2013
4	Colorectal Neoplasms (Colorectal Cancer) 01/2015 - 07/2006
4	Neoplasm Metastasis (Metastasis) 01/2013 - 01/2007
3	Cholangiocarcinoma 10/2019 - 01/2016
3	Neutropenia 01/2018 - 12/2011
3	Disease Progression 01/2018 - 01/2013
3	Breast Neoplasms (Breast Cancer) 01/2015 - 01/2012
2	Leukemia 10/2020 - 01/2015
2	Carcinogenesis 10/2020 - 10/2008
2	Hematologic Neoplasms (Hematological Malignancy) 10/2020 - 10/2018
2	Proteus Syndrome 01/2019 - 01/2017
2	Abdominal Pain (Pain, Abdominal) 01/2018 - 10/2010
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2022
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022
1	Prostatic Neoplasms (Prostate Cancer) 01/2022
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2020
1	Multiple Myeloma 11/2019
1	Carcinoma (Carcinomatosis) 01/2019
1	Rare Diseases (Rare Disease) 01/2019
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2018
1	Liver Failure 01/2018
1	Acute Coronary Syndrome 01/2018
1	Acute Kidney Injury (Acute Renal Failure) 01/2018
1	Ascites 01/2018
1	Sepsis (Septicemia) 01/2018
1	Craniosynostoses (Craniosynostosis) 12/2017
1	LEOPARD Syndrome (Syndrome, LEOPARD) 01/2017
1	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 01/2017
1	Hypertrophy 01/2017
1	Endometrial Neoplasms (Endometrial Cancer) 01/2017
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/2017
1	Sickle Cell Anemia (Hemoglobin S Disease) 01/2017
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2013
1	Osteolysis 01/2012
1	Dehydration (Water Stress) 12/2011
1	Leukopenia 12/2011
1	Thrombocytopenia (Thrombopenia) 12/2011
1	Vomiting 12/2011
1	Anorexia 10/2010
1	Respiratory Sounds (Crackle) 10/2010
1	Infections 07/2008

Drug/Important Bio-Agent (IBA)

9	ARQ 197IBA 01/2018 - 12/2011
8	Sorafenib (BAY 43-9006)FDA Link 02/2018 - 05/2011
7	MiransertibIBA 01/2019 - 01/2015
5	derazantinibIBA 10/2019 - 01/2016
3	Tyrosine Kinase InhibitorsIBA 10/2020 - 04/2017
3	Biomarkers (Surrogate Marker)IBA 01/2018 - 11/2016
2	isatuximabIBA 01/2022 - 01/2022
2	AntibodiesIBA 01/2022 - 11/2019
2	ibrutinibIBA 10/2020 - 10/2018
2	Agammaglobulinaemia Tyrosine KinaseIBA 10/2020 - 10/2018
2	Proteins (Proteins, Gene)FDA Link 10/2020 - 01/2007
2	Phosphotransferases (Kinase)IBA 10/2020 - 01/2016
2	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 10/2019 - 01/2016
2	Paclitaxel (Taxol)FDA LinkGeneric 04/2017 - 01/2015
2	Pharmaceutical PreparationsIBA 01/2017 - 01/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2016 - 01/2007
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2007 - 07/2006
1	cemiplimabIBA 01/2022
1	B7-H1 AntigenIBA 01/2022
1	Thomsen-Friedenreich antibodiesIBA 01/2022
1	Tyrosine (L-Tyrosine)FDA Link 10/2020
1	ARQ531IBA 10/2020
1	RNA (Ribonucleic Acid)IBA 10/2020
1	Proteasome Endopeptidase Complex (Proteasome)IBA 10/2020
1	Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA 10/2019
1	Therapeutic UsesIBA 01/2019
1	Diethylnitrosamine (N-Nitrosodiethylamine)IBA 02/2018
1	Carboplatin (JM8)FDA LinkGeneric 04/2017
1	IntegrinsIBA 01/2017
1	Aligeron (AS 2)IBA 01/2017
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2017
1	Platelet Glycoprotein GPIb-IX Complex (Glycoprotein Ib)IBA 01/2017
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2017
1	P-SelectinIBA 01/2017
1	Hydroxyurea (Hydrea)FDA LinkGeneric 01/2017
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 11/2016
1	Methylnitronitrosoguanidine (MNNG)IBA 11/2016
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 11/2016
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 11/2016
1	Adenosine Triphosphate (ATP)IBA 01/2016
1	Zoledronic Acid (Zometa)FDA Link 01/2013
1	Small Interfering RNA (siRNA)IBA 01/2012
1	Alanine Transaminase (SGPT)IBA 10/2010
1	darinaparsinIBA 10/2010
1	Hormones (Hormone)IBA 10/2008
1	LeptinIBA 10/2008
1	Proline (L-Proline)FDA Link 07/2008

Therapy/Procedure

11	Therapeutics 01/2022 - 12/2011
3	Drug Therapy (Chemotherapy) 01/2022 - 07/2006
1	Castration 01/2022
1	Immunotherapy 01/2022
1	Organ Transplantation 11/2019
1	Precision Medicine 01/2019
1	Investigational Therapies (Experimental Therapy) 04/2017
1	Oral Administration 01/2017
1	Drug Tapering 05/2011